Please login to the form below

Not currently logged in
Email:
Password:

Internis appoints Sandoz's Paul Tredwell

He joins the UK bone disorder-focused start-up as chief operating officer

Internis Paul TredwellInternis has poached Sandoz's former head of biopharmaceuticals Paul Tredwell to serve as its chief operating officer.  

Tredwell joins the UK bone disorder-focused start-up after serving at Sandoz for four years, during which time he set up a new division in the UK and was directly responsible for managing the sales, marketing and medical functions.  

Prior to his time with the firm, which operates as Novartis' generics division, Tredwell spent eight years with Shire in senior sales and marketing positions. These included leading the UK specialist sales teams as well as its commercial and NHS teams.  

Paul began his career in the pharmaceutical industry with Galen 16 years ago where he served as area sales manager.  

In his new role Tredwell will be tasked with driving sales of Internis' calcium products FultiumD3 and Accrete D3, as well as a number of new products the firm plans to introduce early next year.  

He will report to Internis' joint CEO Alan Walker who said: "We are delighted to have Paul Tredwell join our team. Paul is a recognised global leader in his field.  

“His skills, knowledge and extensive experience in the industry, as well as his ability to deliver results, make him the ideal candidate to lead Internis into the next exciting phase of its development."

27th August 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...